Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series
Laila Rkieh,
Wasim S. El Nekidy,
Leen Oyoun Alsoud,
Adnan Alatoom,
Rania El Lababidi,
Mohamad Mooty,
Ahmad R. Nusair
Affiliations
Laila Rkieh
Trillium Health Partners Mississauga Hospital, Mississauga, ON, Canada; Correspondence to: Trillium Health Partners Mississauga Hospital, 100 Queensway Street West, Mississauga, ON, Canada.
Wasim S. El Nekidy
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
Leen Oyoun Alsoud
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Adnan Alatoom
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; National Reference Laboratory, Abu Dhabi, United Arab Emirates
Rania El Lababidi
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Mohamad Mooty
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Ahmad R. Nusair
Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA
Echinocandins are generally excluded in the treatment of Candida-related urinary tract infections due to their poor urinary concentration. In the presence of fluconazole resistant Candida species, such as C. Glabrata and C. auris, alternative therapies are needed. We herein report the use of caspofungin for the treatment of 10 patients with candiduria, including C. auris. Mycological cure was achieved in 6 of 7 patients and clinical cure was achieved in 8 of 10 patients. Larger studies are needed to confirm our findings.
